To evaluate the effect of combined use of ibandronate and eldecalcitol for 6 to 12 months on bone mineral density (BMD) and bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis. Methods. BMD and bone strength of the proximal femur were evaluated in 78 postmenopausal women (mean age, 73.6 years) who underwent treatment for osteoporosis with combined use of ibandronate and eldecalcitol for at least 6 months. BMD was measured at the lumbar spine, femoral neck, and total hip using dual-energy X-ray absorptiometry (DXA) at baseline and every 6 months thereafter. Hip structure analysis of the narrow neck and intertrochanter was performed by a radiologist using DXA images. Results. Respectively for the lumbar spine, femoral neck, and total hip, BMD significantly increased (from baseline) by 4.54%, 2.31%, and 1.56% at 6 months and by 5.92%, 3.02%, and 2.70% at 12 months. In hip structure analysis, most parameters improved significantly. Respectively for the narrow neck and Journal of Orthopaedic Surgery 2016;24(3):362-6 intertrochanter, BMD significantly increased (from baseline) by 2.37% and 2.71% at 6 months and by 3.46% and 3.52% at 12 months; cross-sectional area significantly increased by 1.83% and 3.39% at 6 months and by 2.91% and 3.46% at 12 months; section modulus significantly increased by 2.42% and 4.11% at 6 months and by 4.84% and 3.26% at 12 months; cortical thickness significantly increased by 2.49% and 3.33% at 6 months and by 3.73% and 3.37% at 12 months; and buckling ratio significantly decreased by 2.97% and 2.57% at 6 months and by 3.86% and 2.99% at 12 months. Conclusion. Combined use of ibandronate and eldecalcitol for 6 months significantly improved bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis.
with osteoporosis, fractures can recur within a short duration. It is therefore important to improve bone mineral density (BMD) and bone strength as soon as possible. Bisphosphonates are most commonly prescribed for osteoporosis. Nonetheless, a significant decrease in fracture risk occurs only after treatment for 12 months for vertebral fracture, 18 months for hip fracture, and 24 months for nonvertebral fracture. 2 Combined use of alendronate and active vitamin D 3 (alfacalcidol) significantly reduces the risk of vertebral fractures after 6 months. 3 The effect of combined use of bisphosphonate and active vitamin D 3 for a short duration on BMD and bone strength in the proximal femur is not well known. Intravenous ibandronate 1 mg/month shows noninferiority to daily oral risedronate in the incidence of vertebral fractures among Japanese patients with primary osteoporosis. 4 Eldecalcitol 0.75 μg/day is a novel active vitamin D 3 analogue with a hydroxypropoxy group at the 2β-position of 1α, 25-dihydroxyvitamin D 3 . [5] [6] [7] This study evaluated the effect of combined use of ibandronate and eldecalcitol for 6 to 12 months on BMD and bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis.
Materials and Methods
This study was conducted according to the Declaration of Helsinki. 78 postmenopausal women with a mean age of 73.6 (standard deviation [SD], 7.30) years and a mean body mass index of 21.8 (SD, 2.98) kg/m 2 who underwent treatment for osteoporosis with combined use of ibandronate and eldecalcitol for at least 6 months were evaluated for BMD and bone strength of the proximal femur. They were community-dwelling and ambulatory and had a mean neck shaft angle of 129.8º (SD, 4.67º). Their serum calcium level (adjusted by serum albumin level) and the ratio of urinary calcium/creatine level were measured at baseline and every 3 to 6 months and found to be within the normal range (8.6-10.2 mg/dl and <0.3, respectively) throughout the study.
According to the Japanese diagnostic criteria, 8 osteoporosis was defined as low BMD (T score, ≤-2.5) or presence of osteoporotic fracture. No patient had any secondary cause of osteoporosis, urinary stones, previous treatment with glucocorticoids or drugs that could affect bone metabolism, any fracture of the proximal femur, or new fracture during treatment.
BMD of the lumbar spine, femoral neck, and total hip was measured using dual-energy X-ray absorptiometry (DXA) at baseline and every 6 months, with a hip positioner used to confine the leg in abduction and internal rotation (15º). 9 Hip structure analysis 10,11 of the narrow neck (traversing the narrowest width of the femoral neck) and intertrochanter (along the bisector of the shaft and femoral neck axes) was performed by a radiologist using DXA images. Briefly, DXA images were converted into bone mass images in which pixel values represent bone mass. The parameters evaluated were areal BMD, inner diameter, outer diameter, cortical thickness, cross-sectional area (for resistance to forces along the long axis), section modulus (for resistance to bending forces), and buckling ratio (for cortical stability). 12, 13 Based on a preceding study, the mean precision error for hip structure analysis of the narrow neck and intertrochanter ranged from 0.8% to 4.7% (mean, 2.2%). 14, 15 Baseline and follow-up results were compared using the paired t-test. A p value of <0.05 was considered statistically significant.
results
Of the 78 patients, data of 76 and 46 patients at 6 and 12 months, respectively, were analysed. At 6 months, data were defective in 2 patients. At 12 months, 32 patients did not continue the treatment until 12 months.
Respectively for the lumbar spine, femoral neck, and total hip, BMD significantly increased (from baseline) by 4.54%, 2.31%, and 1.56% at 6 months and by 5.92%, 3.02%, and 2.70% at 12 months (Table) .
In hip structure analysis, most parameters improved significantly (Table) . Respectively for the narrow neck and intertrochanter, BMD significantly increased (from baseline) by 2.37% and 2.71% at 6 months and by 3.46% and 3.52% at 12 months; crosssectional area significantly increased by 1.83% and 3.39% at 6 months and by 2.91% and 3.46% at 12 months; section modulus significantly increased by 2.42% and 4.11% at 6 months and by 4.84% and 3.26% at 12 months; cortical thickness significantly increased by 2.49% and 3.33% at 6 months and by 3.73% and 3.37% at 12 months; and buckling ratio significantly decreased by 2.97% and 2.57% at 6 months and by 3.86% (p>0.05) and 2.99% at 12 months.
discussion
Bone strength primarily reflects the integration of bone density and bone quality, including both material and structural properties. 1 BMD and hip structure analysis parameters are representative surrogate markers used to evaluate osteoporosis treatment. [16] [17] [18] [19] [20] [21] [22] [23] It is important to improve BMD and bone strength within a short period, because in patients with osteoporosis, fractures can recur within a short period of 32 weeks, 24 8 months, 25 or one year. 26 Combined use of ibandronate and eldecalcitol significantly improved BMD and bone strength of the proximal femur within 6 months. It is particularly useful in patients with high fracture risk and no renal dysfunction. When treatment is long term or when serum calcium level and/or the ratio of urinary calcium/creatine level exceeds the normal range, eldecalcitol should be stopped or changed to vitamin D 3 .
Ibandronate for 12 months significantly increases the cross-sectional area, outer diameter, and endosteal diameter of the narrow neck, and the cross-sectional area and moment of inertia of the intertrochanter. 27 Alendronate and risedronate for 6 months improves bone strength although not significantly. 22 In our study, ibandronate and eldecalcitol for 6 months significantly improved BMD and most hip structure analysis parameters.
Ibandronate may have a greater potential to affect cortical bone, because it has a lower affinity to hydroxyapatite. This results in weaker uptake, higher desorption, lower reattachment, and more diffusion in bone within a short period. 28 Differences in binding affinity are likely to be reflected in the apparent clinical differences in these bisphosphonates. Indeed, the risk of any fracture is significantly lower in patients prescribed monthly ibandronate than weekly bisphosphonate (adjusted relative risk=0.65, p=0.033). 29 Intravenous bisphosphonates are more bioavailable than oral bisphosphonates. A higher ibandronate dose (annual cumulative exposure ≥10.8 mg) significantly reduces the risk of non-vertebral fracture in postmenopausal women. 30 Eldecalcitol has effects on serum calcium metabolism as active vitamin D 3 , and exerts a larger effect on cortical bone than alfacalcidol; eldecalcitol has the potential to improve the biomechanical properties of the proximal femur. 31 There were several limitations to this study. Serum vitamin D and parathyroid hormone levels were not assessed, because the Japanese health insurance system does not cover such measurements in patients with osteoporosis. In addition, there was no placebo group, and the number of patients was insufficient to evaluate the association between changes in bone strength and fracture incidence. 
Table Percentage change in bone mineral density (BMD) and hip structure analysis parameters from baseline to 6 and 12 months
Nonetheless, this study can be used to assess the pharmacological effects of the drugs and determine the best therapeutic strategy.
conclusion Combined use of ibandronate and eldecalcitol for 6 months significantly improved bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis.
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